Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
32.00    -0.75 (-2.29%)
Bid:
31.00
Ask:
33.00
Spread: 2.00 (6.452%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Half Year Trading Update

12 Nov 2013 07:00

RNS Number : 7510S
Ilika plc
12 November 2013
 



Ilika plc

("Ilika" or the "Company")

 

Half Year Trading Update

 

Ilika (AIM: IKA), the advanced materials discovery company, announces a trading update for the six months ended 31 October 2013. Ilika will announce Interim Results for the six months ended 31 October on 29 January 2014.

 

Operational Review

 

The Company has continued to make progress with developing and licensing its proprietary materials IP. With the goal of driving towards generating licensing revenue, Ilika is currently managing active OEM trials with two separate products from its portfolio: a polymer surface used for cell growth and a low-cost fuel cell catalyst. Technical development of these two products is substantially complete, with the focus now being on market introduction. The polymer is a heritage product from its biomaterial portfolio and is being out-licensed on Ilika's behalf by BioBM, a specialist life science marketing company. Following the delivery of a kg-scale quantity of its low cost fuel cell catalyst, OEM trials have commenced with three global OEM's and a trial with a further automotive OEM will commence in Q1 2014. 

 

Technology development activities are focused on the Company's solid-sate battery technology. Initial cell performance data have been encouraging and the focus of the programme is now shifting to stacking multiple cells to make higher capacity devices. The benefits of the technology remain of interest to a broad range of sectors spanning different battery scales including micro-batteries for wireless sensors, portable consumer electronics and larger scale automotive.

 

A new high growth sector for the Company's technology platform is the aerospace sector, where Ilika has entered into initial relationships with two of the world's largest aerospace companies. Further activities are expected to be supported by the Aerospace Technology Institute, which has recently been established to deploy £2 billion of funding for the UK aerospace industry over the next seven years.

 

Financial Review

 

Total revenue for the period has shown year-on-year growth of 55%, reaching £0.62m (H1 2012: £0.4m).

 

Ilika has expanded its active customer base in the period from five in the comparable period last year, to nine in the current year. The geographical spread of revenues has also become more balanced due to a stronger business development performance in Europe. In the previous year, 70% of revenues originated with Japanese customers, whereas in the current year to date, 45% of revenues have come from Europe and 45% from Japan. Business development efforts in the USA are expected result in an increased proportion of revenue in the second half.

 

Cash and cash equivalents at the period end were in excess of £1.4m

 

As announced previously, an overview of the business will be provided later today, Tuesday 12 November 2013, at the Black Bar at Rocket, 6 Adams Court, Old Broad Street, London, EC2N 1DX and will be followed by drinks and canapés. If you wish to attend please contact Walbrook PR Ltd.

 

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan, Nominated Adviser

 

James Black, Corporate Broking

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or ilika@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Paul Cornelius

Mob: 07827 879 460

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFFLFUFFDSESF
Date   Source Headline
21st May 20267:00 amRNSIlika Trading Update and Notice of Results
10th Apr 20264:01 pmRNSCollaboration with Brompton Bicycles
18th Mar 20267:00 amRNSPositive Feedback on Safety of Goliath Cells
10th Mar 20267:00 amRNSFirst Commercial Delivery to Cirtec Medical
24th Feb 202610:21 amRNSAward of Share Options
19th Feb 20267:00 amRNS-RIlika at Yellowstone Investor Evening: Replacement
22nd Jan 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSIlika Secures Stereax Electrode Order from Cirtec
18th Dec 20257:00 amRNSInitial Stereax M300 Shipments
11th Dec 20257:00 amRNSIlika Ships 10Ah Goliath Battery Prototypes
20th Nov 20257:00 amRNSTrading Update & Notice of Half-Year Results
21st Oct 20257:00 amRNSCommissioning Complete for Goliath Pilot Line
1st Oct 202512:00 pmRNSExercise of Options and Total Voting Rights
23rd Sep 20253:43 pmRNSResult of AGM & Award of Executive Share Options
22nd Sep 20257:00 amRNSStart of Primed Solid-State Battery Programme
28th Aug 20257:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20257:00 amRNSStereax Battery Milestone at Cirtec Medical
17th Jul 20258:56 amRNSHolding(s) in Company
17th Jul 20257:00 amRNSFinal Results
15th Jul 20257:00 amRNSAward of Government Grant Funding
11th Jun 20252:09 pmRNSNotice of Results
4th Jun 20252:14 pmRNSHolding(s) in Company
3rd Jun 20251:57 pmRNSHolding(s) in Company
28th May 20256:00 pmRNSResult of Oversubscribed Retail Offer
22nd May 20252:16 pmRNSRetail Offer for up to £0.5 million
22nd May 20251:53 pmRNSResult of Placing & Director Subscription
21st May 20255:14 pmRNSProposed Capital Raise
7th May 202510:03 amRNS-RIlika announces 2025 Investor Day
1st May 20257:00 amRNSGoliath P1 Cells Validated by Customer Testing
15th Apr 20257:00 amRNSGoliath Battery Achieves Scale-up Milestone
6th Mar 20257:00 amRNSGoliath Development Progress
27th Feb 20257:00 amRNSAward & Exercise of Share Options
6th Feb 20253:49 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSGoliath Scale-up Progress
21st Jan 20257:00 amRNSHalf-year Results
9th Jan 20257:00 amRNSStereax Equipment Commissioning Completed
19th Dec 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
22nd Nov 20242:18 pmRNSAIM Rule 17 Schedule 2(g) Update
20th Nov 20247:00 amRNSGoliath D6 milestone reached
15th Nov 20247:00 amRNSTrading Update & Notice of Half-Year Results
10th Oct 20241:49 pmRNSHolding(s) in Company
3rd Oct 20247:00 amRNSFurther Goliath Technical Milestone Achieved
29th Aug 20247:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20247:00 amRNSFinal Results
2nd Jul 20247:00 amRNSKey Technology Validation Milestone
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
31st May 20242:29 pmRNSHolding(s) in Company
29th May 202411:52 amRNSResults of General Meeting Open Offer and TVR
22nd May 20247:00 amRNSKey Goliath Technology Validation Milestone
16th May 20247:00 amRNSTrading Update, Notice of Results & Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.